CA1094455A - Tumor antidote - Google Patents

Tumor antidote

Info

Publication number
CA1094455A
CA1094455A CA277,458A CA277458A CA1094455A CA 1094455 A CA1094455 A CA 1094455A CA 277458 A CA277458 A CA 277458A CA 1094455 A CA1094455 A CA 1094455A
Authority
CA
Canada
Prior art keywords
tumor
formula
antidote
carbon atoms
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA277,458A
Other languages
English (en)
French (fr)
Inventor
Paul G. Munder
Otto Westphal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Application granted granted Critical
Publication of CA1094455A publication Critical patent/CA1094455A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA277,458A 1976-05-04 1977-05-03 Tumor antidote Expired CA1094455A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP2619686.1 1976-05-04
DE2619686A DE2619686C2 (de) 1976-05-04 1976-05-04 Verwendung eines Lysolecithins zur Tumorbehandlung

Publications (1)

Publication Number Publication Date
CA1094455A true CA1094455A (en) 1981-01-27

Family

ID=5977045

Family Applications (1)

Application Number Title Priority Date Filing Date
CA277,458A Expired CA1094455A (en) 1976-05-04 1977-05-03 Tumor antidote

Country Status (15)

Country Link
JP (1) JPS52134027A (cs)
AU (1) AU517586B2 (cs)
BE (1) BE854270A (cs)
CA (1) CA1094455A (cs)
DE (1) DE2619686C2 (cs)
FR (1) FR2364656A1 (cs)
GB (1) GB1583661A (cs)
IE (1) IE44927B1 (cs)
IL (1) IL51988A (cs)
IT (1) IT1071329B (cs)
LU (1) LU77248A1 (cs)
NL (1) NL189672C (cs)
NZ (1) NZ183981A (cs)
SE (1) SE7705071L (cs)
ZA (1) ZA772649B (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5396311A (en) * 1977-01-29 1978-08-23 Toyama Chem Co Ltd Anti-cander drugs containing lysolecithins
JPS5528955A (en) * 1978-08-24 1980-02-29 Toyama Chem Co Ltd Novel glycerophosphoric acid derivative, its salt, their preparation, and carcinostatic agent containing the same.
GB2046092B (en) * 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4408052A (en) * 1980-02-27 1983-10-04 Takeda Chemical Industries, Ltd. Phospholipid carbamates
US4551532A (en) * 1980-05-08 1985-11-05 Takeda Chemical Industries, Ltd. Ethylene glycol derivatives having anti-protozoan, anti-fungal and anti-tumor activity
US4444766A (en) * 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
JPS5772914A (en) * 1980-10-22 1982-05-07 Takeda Chem Ind Ltd Antitumor agent
EP0061872B1 (en) * 1981-03-30 1985-08-07 Takeda Chemical Industries, Ltd. Ethyleneglycol derivatives, their production and use
DE3127503A1 (de) * 1981-07-11 1983-02-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3131524A1 (de) * 1981-08-08 1983-02-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung physiologischer effektoren
US4562179A (en) * 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
DE3239817A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue glycerinderivate zur synthese von phospholipiden
DE3239858A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue d-mannitderivate als ausgangsprodukte zur synthese von phospholipiden
DE3368933D1 (en) * 1982-09-21 1987-02-12 Fujisawa Pharmaceutical Co Phosphate derivatives, process for preparation thereof and pharmaceutical compositions of the same
US4710579A (en) * 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
US4761404A (en) * 1985-07-01 1988-08-02 Merck & Co., Inc. Phospholipid analogs useful as PAF synthesis inhibitors
DE3662197D1 (en) 1985-07-15 1989-04-06 Takeda Chemical Industries Ltd 2-alkanoyloxypropane derivatives, their production and use
JPS6294A (ja) * 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
JP2561478B2 (ja) * 1986-07-22 1996-12-11 武田薬品工業株式会社 グリセリン誘導体
US4888328A (en) * 1988-03-10 1989-12-19 Hoeschst-Roussel Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
US5036152A (en) * 1988-03-10 1991-07-30 Hoechst-Roussel Pharmaceuticals Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
DE3906952A1 (de) * 1989-03-04 1990-09-06 Boehringer Mannheim Gmbh (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel
DE3918082A1 (de) * 1989-06-02 1991-01-24 Max Planck Gesellschaft Mittel gegen autoimmunerkrankungen
DE3935580C2 (de) * 1989-10-25 1998-05-28 Medmark Pharma Gmbh Verwendung eines pharmazeutischen Wirkstoffes zur Behandlung von HIV-Infektionen
WO1992019627A2 (en) * 1991-04-25 1992-11-12 The University Of British Columbia Phosphonates and phosphinates as anti-cancer, -inflammatory, -allergy and -myocarditis agents
ES2034885B1 (es) * 1991-07-10 1994-03-01 Menarini Lab Procedimiento para la preparacion de cetoalquilglicerofosfolipidos.
FI971494A7 (fi) * 1994-10-14 1997-04-10 Zeneus Pharma Ltd Eetterilipidiloposomit sekä niiden terapeuttinen käyttö
US6007839A (en) * 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5965159A (en) 1996-02-16 1999-10-12 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
USRE39042E1 (en) * 1996-02-16 2006-03-28 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US6667053B1 (en) 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US6135426A (en) * 1998-01-07 2000-10-24 Briggs And Stratton Corporation Priming system for internal combustion engines
CA2669012C (en) 2006-11-10 2017-06-20 Alphaptose Gmbh Combinations of edelfosine and anti-cancer agents for treatment of cancer
JP5352466B2 (ja) 2006-11-10 2013-11-27 アルファプトーゼ ゲーエムベーハー トリ置換グリセロール化合物を含む経口投与剤形、経口投与剤形の調製方法、経口投与剤形の使用方法
US20100136029A1 (en) 2006-12-20 2010-06-03 Universitatsklinikum Hamburg-Eppendorf Use of Tri-Substituted Glycerol Compounds for the Treatment of Hematological Malignancies
US8637688B2 (en) * 2006-12-20 2014-01-28 Julia Diederichs Topical dosage form comprising tri-substituted glycerol compounds
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009341C3 (de) * 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2033361C3 (de) * 1970-07-06 1980-02-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Acylpropandiol-(13)-phosphorsäurecholinester und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
JPS52134027A (en) 1977-11-09
BE854270A (fr) 1977-11-04
IT1071329B (it) 1985-04-02
NZ183981A (en) 1980-04-28
NL189672B (nl) 1993-01-18
AU2481977A (en) 1978-11-09
IE44927B1 (en) 1982-05-19
IE44927L (en) 1977-11-04
NL189672C (nl) 1993-06-16
AU517586B2 (en) 1981-08-13
DE2619686C2 (de) 1986-08-07
LU77248A1 (cs) 1977-12-13
DE2619686A1 (de) 1977-11-24
FR2364656B1 (cs) 1980-03-07
GB1583661A (en) 1981-01-28
IL51988A (en) 1981-05-20
SE7705071L (sv) 1977-11-05
IL51988A0 (en) 1977-07-31
ZA772649B (en) 1978-04-26
FR2364656A1 (fr) 1978-04-14
NL7704723A (nl) 1977-11-08
JPS6146455B2 (cs) 1986-10-14

Similar Documents

Publication Publication Date Title
CA1094455A (en) Tumor antidote
KR890701562A (ko) 면역조절 아자스 피란류
JPS5671074A (en) 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) Imidazole derivative
KR910016931A (ko) 과콜레스테린혈증 치료제
DE2710327C3 (de) Verwendung von Benzaldehyd
EP0210753A3 (en) Anti-tumor medicament
EP0182317A2 (en) Antineoplastic agent
Bicker et al. Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanaziridinyl-(1)-]-2-[-2-carbamoylaziridinyl-(l)]-propane BM 12 531
KR0159934B1 (ko) 항종양제
Kern et al. Observations on the toxicity of methyl‐silicone
JPS5673046A (en) Decaprenylamine derivative
JP2648176B2 (ja) 制癌剤
DE2314387A1 (de) Arzneimittel zur behandlung boesartiger neubildungen, vorzugsweise von haemoblastosen und chorionepitheliom
EP0139005A1 (en) Antitumor composition, method for treating tumor, and use of the composition for treating tumor
US5008287A (en) Pharmaceutical compositions having antineoplastic activity
GB1354734A (en) Pharmaceutical compositions comprising aminoguanidine derivatives
EP0482172A1 (en) Anti-tumor agents having reduced toxicity on the basis of cytostatic agents and xanthogenates
Schueler et al. Synthesis and evaluation of a new ganglionic blocking agent
JPH0120128B2 (cs)
JPS5612312A (en) Carcinostatic agent
KR890000381B1 (ko) 아실아미노페놀 유도체의 제조방법
JPH0548207B2 (cs)
Froelich The effect of 5-heptyl-2-thiohydantoin on experimental tuberculosis
JPS61130222A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
MKEX Expiry